Image guided biodistribution and pharmacokinetic studies of theranostics

Theranostics

Volumn 2, Issue 11, 2012, Pages 1040-1053

  Ding, Hong ^a,b   Wu, Fang ^b  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibody; Biodistribution; Image; Nanoparticles; Pharmacokinetic; Theranostics

Indexed keywords

NANOPARTICLE; QUANTUM DOT;

BIOLUMINESCENCE; BLOOD BRAIN BARRIER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FLUORESCENCE IMAGING; HUMAN; IMAGING; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL IMAGING; OPTICS; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERANOTICS;

ANTIBODY.; BIODISTRIBUTION; IMAGE; NANOPARTICLES; PHARMACOKINETIC; THERANOSTICS;

ANIMALS; BLOOD-BRAIN BARRIER; DIAGNOSTIC IMAGING; HUMANS; NANOPARTICLES; OPTICAL IMAGING; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 84870523966     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4652     Document Type: Review

References (111)

1. Grosu AL, Weber WA, Franz M et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. International journal of radiation oncology, biology, physics 2005; 63: 511-519.
2. Hofmann M, Steinke F, Scheel V et al. MRI-Based Attenuation Correction for PET/MRI: A Novel Approach Combining Pattern Recognition and Atlas Registration. Journal of Nuclear Medicine 2008; 49: 1875-1883.
3. Wintermark M, Meuli R, Browaeys P et al. Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. Neurology 2007; 68: 694-697.
4. Visser BC, Yeh BM, Qayyum A et al. Characterization of Cystic Pancreatic Masses: Relative Accuracy of CT and MRI. American Journal of Roentgenology 2007; 189: 648-656.
5. Pien HH, Fischman AJ, Thrall JH, Sorensen AG. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discovery Today 2005; 10: 259-266.
6. Zerizer I, Tan K, Khan S et al. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. European Journal of Radiology 2010; 73: 504-509.
7. Rai P, Mallidi S, Zheng X et al. Development and applications of photo-triggered theranostic agents. Advanced Drug Delivery Reviews 2010; 62: 1094-1124.
8. An G, Wu F, Morris ME. 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice. Pharm Res 2011; 28: 1090-1099.
9. Wu F, Zhang Z, Ding H. Simple high-performance liquid chromatographic method for the determination of tetramethylpyrazine phosphate in very small volumes of dog plasma: application to a pharmacokinetic study. J Chromatogr Sci 2006; 44: 13-17.
10. Masutomi T, Onishi H, Takahashi Y, Machida Y. Biodistribution study using Egg Protein ELISA kit after administration of FITC-labeled ovalbumin solution and its double liposomes in the in situ loop method, and its implication in oral immunization. Curr Drug Deliv 2010; 7: 447-452.
11. Hong H, Goel S, Zhang Y, Cai W. Molecular Imaging with Nucleic Acid Aptamers. Current Medicinal Chemistry 2011; 18: 4195-4205.
12. Pickhardt P, Park S, Hahn L et al. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. European Radiology 2012; 22: 1075-1082.
13. Funkhouser J. Reinventing pharma: The theranostic revolution. Current Drug Discovery 2002; 2: 17-19.
14. Li M KH, et al. Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors. Theranostics 2012; 2: 76-85.
15. Ray P DA. Reporter Gene Imaging in Therapy and Diagnosis. Theranostics 2012; 2: 333-334.
16. Palm S, Enmon RM, Matei C et al. Pharmacokinetics and Biodistribution of 86Y-Trastuzumab for 90Y Dosimetry in an Ovarian Carcinoma Model: Correlative MicroPET and MRI. Journal of Nuclear Medicine 2003; 44: 1148-1155.
17. Wen S, Liu D-F, Liu Z et al. OxLDL-targeted iron oxide nanoparticles for in vivo MRI detection of perivascular carotid collar induced atherosclerotic lesions in ApoE-deficient mice. Journal of Lipid Research 2012; 53: 829-838.
18. Vyjayanti VN, Rao KS. DNA double strand break repair in brain: Reduced NHEJ activity in aging rat neurons. Neuroscience Letters 2006; 393: 18-22.
19. Reddy S, Robinson MK. Immuno-positron emission tomography in cancer models. Semin Nucl Med 2010; 40: 182-189.
20. Voss SD, Smith SV, DiBartolo N et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A 2007; 104: 17489-17493.
21. Dearling JL, Voss SD, Dunning P et al. Imaging cancer using PET-the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol 2011; 38: 29-38.
22. Lancelot S, Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 2010; 31: 411-417.
23. Bading JR, Horling M, Williams LE et al. Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice. Cancer Biother Radiopharm 2008; 23: 399-409.
24. Herbertson RA, Tebbutt NC, Lee FT et al. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 2009; 15: 6709-6715.
25. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET Imaging of Integrin αVβ3 Expression. Theranostics 2011; 1: 48-57.
26. Jacobson OJ, Weiss ID, Szajek LP et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 2011; 1: 251-262.
27. Liu S LH, et al. PET Imaging of Integrin Positive Tumors Using 18F Labeled Knottin Peptides. Theranostics 2011; 1: 403-412.
28. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558.
29. Nagengast WB, de Vries EG, Hospers GA et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313-1319.
30. Paudyal B, Paudyal P, Oriuchi N et al. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011; 102: 117-121.
31. Hong H, Zhang Y, Engle JW et al. In vivo targeting and positron emission tomography imaging of tumor vasculature with 66Ga-labeled nano-graphene. Biomaterials 2012; 33: 4147-4156.
32. Petersen AL, Binderup T, Jølck RI et al. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. Journal of Controlled Release 2012.
33. Pimlott SL, Sutherland A. Molecular tracers for the PET and SPECT imaging of disease. Chemical Society Reviews 2011; 40: 149-162.
34. Schneider DW, Heitner T, Alicke B et al. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J Nucl Med 2009; 50: 435-443.
35. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes & Development 2003; 17: 545-580.
36. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-693.
37. Helbok A, Decristoforo C, Dobrozemsky G et al. Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals. Journal of Liposome Research 2010; 20: 219-227.
38. DeNardo SJ, DeNardo GL, Miers LA et al. Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy. Clinical Cancer Research 2005; 11: 7087s-7092s.
39. Natarajan A, Gruettner C, Ivkov R et al. NanoFerrite Particle Based Radioimmunonanoparticles: Binding Affinity and In Vivo Pharmacokinetics. Bioconjugate Chemistry 2008; 19: 1211-1218.
40. Misri R, Saatchi K, Ng SSW et al. Evaluation of 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nuclear Medicine and Biology 2011; 38: 885-896.
41. Fang Wu, Hong Ding, Zhang Z. Investigation of the in vivo desintegration and transit behavior of Tetramethylpyrazine phosphate pulsincap capsule in the gastrointestinal tract of dogs by gamma scintigraphy. Journal of Biomedical Engineering 2006; 23: 790-794.
42. Tran L, Huitema AD, van Rijswijk MH et al. CD20 antigen imaging with 124 I-rituximab PET/CT in patients with rheumatoid arthritis. Hum Antibodies 2011; 20: 29-35.
43. Bouchelouche K, Tagawa ST, Goldsmith SJ et al. PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med 2011; 41: 29-44.
44. Suga K, Yasuhiko K, Hiyama A et al. F-18 FDG PET/CT findings in a patient with bilateral orbital and gastric mucosa-associated lymphoid tissue lymphomas. Clin Nucl Med 2009; 34: 589-593.
45. Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol 2009; 21: 469-474.
46. Welch MJ. Potential of labeling monoclonal antibodies for positron emission tomography and magnetic resonance imaging. Acta Radiol Suppl 1990; 374: 129-133.
47. Townsend DW, Carney JPJ, Yap JT, Hall NC. PET/CT Today and Tomorrow. Journal of Nuclear Medicine 2004; 45: 4S-14S.
48. Gonzalez Trotter DE, Manjeshwar RM, Doss M et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004; 45: 1237-1244.
49. Heiss WD. The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging 2009; 36 Suppl 1: S105-112.
50. Sharma R, Katz JK. Taxotere chemosensitivity evaluation in mice prostate tumor: validation and diagnostic accuracy of quantitative measurement of tumor characteristics by MRI, PET, and histology of mice tumor. Technol Cancer Res Treat 2008; 7: 175-185.
51. Smith TA. Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br J Radiol 2010; 83: 638-644.
52. Borjesson PK, Jauw YW, Boellaard R et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006; 12: 2133-2140.
53. Alessio AM, Kinahan PE. Improved quantitation for PET/CT image reconstruction with system modeling and anatomical priors. Med Phys 2006; 33: 4095-4103.
54. Minamimoto R, Ito K, Kubota K et al. Clinical Role of FDG PET/CT for Methotrexate-Related Malignant Lymphoma. Clin Nucl Med 2011; 36: 533-537.
55. Freudenberg LS, Jentzen W, Stahl A et al. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2011; 38 Suppl 1: S48-56.
56. Harms HJ, Knaapen P, de Haan S et al. Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET/CT scanner. Eur J Nucl Med Mol Imaging 2011; 38: 930-939.
57. Liang H, Yang Y, Yang K et al. A microPET/CT system for in vivo small animal imaging. Phys Med Biol 2007; 52: 3881-3894.
58. Von Falck C, Rodt T, Halter R et al. Combined microPET/CT for imaging of hepatocellular carcinoma in mice. Front Biosci 2009; 14: 2193-2202.
59. Paudyal P, Paudyal B, Iida Y et al. Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Oncol Rep 2009; 22: 115-119.
60. Xie J, Chen K, Huang J et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010; 31: 3016-3022.
61. Madru R, Kjellman P, Olsson F et al. 99mTc-Labeled Superparamagnetic Iron Oxide Nanoparticles for Multimodality SPECT/MRI of Sentinel Lymph Nodes. Journal of Nuclear Medicine 2012; 53: 459-463.
62. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002; 2: 11-18.
63. Hoppin J, Orcutt KD, Hesterman JY et al. Assessing antibody pharmacokinetics in mice with in vivo imaging. J Pharmacol Exp Ther 2011; 337: 350-358.
64. Ding H, Yong K-T, Roy I et al. Gold Nanorods Coated with Multilayer Polyelectrolyte as Contrast Agents for Multimodal Imaging. The Journal of Physical Chemistry C 2007; 111: 12552-12557.
65. Xu Y, Chang E, Liu H et al. Proof-of-Concept Study of Monitoring Cancer Drug Therapy with Cerenkov Luminescence Imaging. Journal of Nuclear Medicine 2012; 53: 312-317.
66. Wu C, Mino K, Akimoto H et al. In vivo far-red luminescence imaging of a biomarker based on BRET from Cypridina bioluminescence to an organic dye. Proceedings of the National Academy of Sciences 2009; 106: 15599-15603.
67. Leblond F, Davis SC, Valdes PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B 2010; 98: 77-94.
68. de Wet JR, Wood KV, DeLuca M et al. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987; 7: 725-737.
69. Heim R, Cubitt AB, Tsien RY. Improved green fluorescence. Nature 1995; 373: 663-664.
70. Wu F, Tamhane M, Morris M. Pharmacokinetics, Lymph Node Uptake, and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab After IV and SC Administration in Mice. The AAPS Journal 2012; 14: 252-261.
71. Wu F, Bhansali SG, Tamhane M et al. Noninvasive real-time fluorescence imaging of the lymphatic uptake of BSA-IRDye 680 conjugate administered subcutaneously in mice. Journal of Pharmaceutical Sciences 2012; 101: 1744-1754.
72. Wu F, Bhansali S, Law W et al. Fluorescence Imaging of the Lymph Node Uptake of Proteins in Mice after Subcutaneous Injection: Molecular Weight Dependence. Pharmaceutical Research 2012; 29: 1843-1853.
73. Zou P, Xu S, Povoski SP et al. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 2009; 6: 428-440.
74. Hulper P, Schulz-Schaeffer W, Dullin C et al. Tumor localization of an anti-TGF-beta antibody and its effects on gliomas. Int J Oncol 2011; 38: 51-59.
75. Liang M, Liu X, Cheng D et al. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem 2010; 21: 1385-1388.
76. Cohen R, Stammes M, de Roos I et al. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Research 2011; 1: 31.
77. Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (Lond) 2008; 3: 83-91.
78. Hu R, Yong KT, Roy I et al. Functionalized near-infrared quantum dots for in vivo tumor vasculature imaging. Nanotechnology 2010; 21: 145105.
79. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998; 281: 2016-2018.
80. Yong KT, Ding H, Roy I et al. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano 2009; 3: 502-510.
81. Yong KT, Hu R, Roy I et al. Tumor targeting and imaging in live animals with functionalized semiconductor quantum rods. ACS Appl Mater Interfaces 2009; 1: 710-719.
82. Law WC, Yong KT, Roy I et al. Aqueous-phase synthesis of highly luminescent CdTe/ZnTe core/shell quantum dots optimized for targeted bioimaging. Small 2009; 5: 1302-1310.
83. Dubertret B, Skourides P, Norris DJ et al. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 2002; 298: 1759-1762.
84. Romero MJ, Van de Lagemaat J, Mora-Sero I et al. Imaging of resonant quenching of surface plasmons by quantum dots. Nano Lett 2006; 6: 2833-2837.
85. Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005; 307: 538-544.
86. Hild WA, Breunig M, Goepferich A. Quantum dots - nano-sized probes for the exploration of cellular and intracellular targeting. Eur J Pharm Biopharm 2008; 68: 153-168.
87. Ding H, Yong KT, Law WC et al. Non-invasive tumor detection in small animals using novel functional Pluronic nanomicelles conjugated with anti-mesothelin antibody. Nanoscale 2011; 3: 1813-1822.
88. Ding H, Yong KT, Roy I et al. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology 2011; 22: 165101.
89. Erogbogbo F, Tien CA, Chang CW et al. Bioconjugation of luminescent silicon quantum dots for selective uptake by cancer cells. Bioconjug Chem 2011; 22: 1081-1088.
90. Erogbogbo F, Yong KT, Hu R et al. Biocompatible magnetofluorescent probes: luminescent silicon quantum dots coupled with superparamagnetic iron(III) oxide. ACS Nano 2010; 4: 5131-5138.
91. Erogbogbo F, Yong KT, Roy I et al. In vivo targeted cancer imaging, sentinel lymph node mapping and multi-channel imaging with biocompatible silicon nanocrystals. ACS Nano 2011; 5: 413-423.
92. Moriyama EH, Zheng G, Wilson BC. Optical molecular imaging: from single cell to patient. Clin Pharmacol Ther 2008; 84: 267-271.
93. Wu F, Wuensch SA, Azadniv M et al. Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses. Mol Pharm 2009; 6: 1506-1517.
94. Liu L, Law WC, Yong KT et al. Multimodal imaging probes based on Gd-DOTA conjugated quantum dot nanomicelles. Analyst 2011; 136: 1881-1886.
95. Law W, Yong K, Roy I et al. Optically and Magnetically Doped Organically Modified Silica Nanoparticles as Efficient Magnetically Guided Biomarkers for Two-Photon Imaging of Live Cancer Cells. J Phys Chem C 2008; 112: 7972-7977.
96. Ding H, Wu F, Huang Y et al. Synthesis and characterization of temperature-responsive copolymer of PELGA modified poly(N-isopropylacrylamide). Polymer 2006; 47: 1575-1583.
97. Zhu L XJ, et al. Real-Time Video Imaging of Protease Expression In Vivo. Theranostics 2011; 1: 18-27.
98. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics 2011; 1: 102-126.
99. Qiao R, Jia Q, Hüwel S et al. Receptor-Mediated Delivery of Magnetic Nanoparticles across the Blood-Brain Barrier. ACS Nano 2012; 6: 3304-3310.
100. Koziara JM, Lockman PR, Allen DD, Mumper RJ. In Situ Blood-Brain Barrier Transport of Nanoparticles. Pharmaceutical Research 2003; 20: 1772-1778.
101. Bonoiu AC, Bergey EJ, Ding H et al. Gold nanorod-siRNA induces efficient in vivo gene silencing in the rat hippocampus. Nanomedicine 2011; 6: 617-630.
102. Chakravarthy KV, Bonoiu AC, Davis WG et al. Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proceedings of the National Academy of Sciences 2010; 107: 10172-10177.
103. Bonoiu AC, Mahajan SD, Ding H et al. Nanotechnology approach for drug addiction therapy: Gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proceedings of the National Academy of Sciences 2009; 106: 5546-5550.
104. Mahajan S. D. RI, Xu GX, Yong K, Ding H., Aalinkeel R., Reynolds J. L., Sykes D. E., Nair B. B., Lin E. Y., Prasad P. N., Schwartz S. A.. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Current HIV Research 2010; 8: 396-404.
105. Koffie RM, Farrar CT, Saidi L-J et al. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proceedings of the National Academy of Sciences 2011; 108: 18837-18842.
106. Banks WA. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. Journal of Neurovirology 1999; 5: 538-555.
107. Weinstein JS, Varallyay CG, Dosa E et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2009; 30: 15-35.
108. Atwal JK, Chen Y, Chiu C et al. A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo. Science Translational Medicine 2011; 3: 84ra43.
109. Yu YJ, Zhang Y, Kenrick M et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target. Science Translational Medicine 2011; 3: 84ra44.
110. Lee HJ, Engelhardt B, Lesley J et al. Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse. Journal of Pharmacology and Experimental Therapeutics 2000; 292: 1048-1052.
111. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnology and Bioengineering 2007; 96: 381-391.